GSK (GSK) Stock Forecast & Price Target

$38.97

-0.24 (-0.61%)

(As of 10/17/2024 ET)

GSK - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 9 Analyst Ratings

Sell
0

Hold
4

Buy
5

Based on 9 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 4 have given a hold rating, 2 have given a buy rating, and 3 have given a strong buy rating for GSK.

Consensus Price Target

$50.00
28.30% Upside

According to the 9 analysts' twelve-month price targets for GSK, the average price target is $50.00. The highest price target for GSK is $53.00, while the lowest price target for GSK is $47.00. The average price target represents a forecasted upside of 28.30% from the current price of $38.97.

Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

GSK Analyst Ratings Over Time

Type	Current Forecast 10/19/23 to 10/18/24	1 Month Ago 9/19/23 to 9/18/24	3 Months Ago 7/21/23 to 7/20/24	1 Year Ago 10/19/22 to 10/19/23
Strong Buy	3 Strong Buy rating(s)	3 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	4 Sell rating(s)
Consensus Price Target	$50.00	$50.00	$50.00	N/A
Forecasted Upside	28.30% Upside	17.84% Upside	27.06% Upside	N/A
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Reduce

The real reason Elon is fully endorsing Trump (Ad)

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.

Watch this new documentary and you’ll discover what Elon knows,

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GSK Stock vs. The Competition

Type	GSK	Medical Companies	S&P 500
Consensus Rating Score	2.89	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	28.34% Upside	12,628.69% Upside	6.31% Upside
News Sentiment Rating	Positive News See Recent GSK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/27/2024	Barclays 3 of 5 stars	E. Field Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/7/2024	Argus 3 of 5 stars	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/8/2024	UBS Group 4 of 5 stars	A. Hauber Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/2/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$52.50 ➝ $53.00	+39.58%
6/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/20/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Holford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$47.00	+6.12%
3/4/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Reduce
3/17/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
2/2/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		GBX 1,350 ➝ GBX 1,400
12/8/2022	AlphaValue Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Buy
12/5/2022	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:27 AM ET.

Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 11, 2024. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

Here are some ways that investors could benefit from investing in GSK plc:

GSK plc has shown strong trading volume recently, indicating increased market interest and potential price movement.
Analysts have given GSK plc positive ratings, with some even upgrading it to a "strong-buy," suggesting confidence in the company's future performance.
GSK plc reported earnings per share of $1.09 for the last quarter, surpassing analyst estimates by $0.09, showcasing strong financial performance.
The company has a solid return on equity of 51.48%, indicating efficient use of shareholder funds to generate profits.
GSK plc has a diverse product portfolio in the pharmaceutical sector, providing stability and potential growth opportunities in different markets.

GSK
Bear Case

Investors should be bearish about investing in GSK plc for these reasons:

GSK plc's stock price has been relatively stagnant, with minor fluctuations, which may not appeal to investors seeking rapid capital appreciation.
The company's debt-to-equity ratio of 0.99 may raise concerns about its leverage levels and ability to manage debt obligations effectively.
While GSK plc has a strong net margin of 12.87%, there could be pressure on margins due to competitive pricing and regulatory challenges in the pharmaceutical industry.
The company's current ratio of 0.82 and quick ratio of 0.54 may indicate potential liquidity issues or difficulties in meeting short-term financial obligations.
GSK plc's beta of 0.65 suggests lower volatility compared to the market, which may limit potential returns for investors seeking higher-risk investments.

GSK Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is $50.00, with a high forecast of $53.00 and a low forecast of $47.00.
: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 4 hold ratings, 2 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GSK shares.
: According to analysts, GSK's stock has a predicted upside of 28.30% based on their 12-month stock forecasts.
: Over the previous 90 days, GSK's stock had 2 upgrades by analysts.
: GSK has been rated by research analysts at Argus, and Barclays in the past 90 days.
: Analysts like GSK more than other "medical" companies. The consensus rating score for GSK is 2.89 while the average consensus rating score for "medical" companies is 2.79. Learn more on how GSK compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Publisher makes HUGE discovery (Ad)

TradingPub Publisher Nate Tucci recently sat down with Chris Pulver to learn about the $100 Challenge. Chris walked him through the trade on a private Zoom call… And he was very clear… This wasn’t a “get rich quick” penny stock scheme… Or an AI stock picker that “cracked the code” of the stock market… It was just a simple, daily trade that anyone could set up at about 9:40 in the morning to target $100 a day or more (starting with just $1,000)...

This page (NYSE:GSK) was last updated on 10/18/2024 by MarketBeat.com Staff

From Our Partners